{"nctId":"NCT00901901","briefTitle":"Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma","startDateStruct":{"date":"2009-05-21","type":"ACTUAL"},"conditions":["Carcinoma, Hepatocellular"],"count":732,"armGroups":[{"label":"Sorafenib (Nexavar, BAY43-9006) + Erlotinib (Tarceva)","type":"EXPERIMENTAL","interventionNames":["Drug: Sorafenib (Nexavar, BAY43-9006)","Drug: Erlotinib (Tarceva)"]},{"label":"Sorafenib (Nexavar, BAY43-9006) + Placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Sorafenib (Nexavar, BAY43-9006)","Drug: Placebo"]}],"interventions":[{"name":"Sorafenib (Nexavar, BAY43-9006)","otherNames":[]},{"name":"Erlotinib (Tarceva)","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients \\> 18 years of age\n* Patients who have a life expectancy of at least 12 weeks\n* Patients with histological or cytologically documented HCC\n* Patients must have at least one tumor lesion that meets both of the following criteria:\n\n  * The lesion can be accurately measured in at least one dimension according to response evaluation criteria in solid tumors (RECIST)\n  * The lesion has not been previously treated with local therapy\n* Patients who have an ECOG PS (Eastern Cooperative Oncology Group Performance Status) of 0 or 1\n* Cirrhotic status of Child-Pugh class A.\n* Patients who give written informed consent prior to any study specific screening procedures with the understanding that the patient has the right to withdraw from the study at any time.\n\nExclusion Criteria:\n\n* History of cardiac disease: congestive heart failure \\> New York Heart Association (NYHA) class 2; active coronary artery disease (CAD); cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin), or uncontrolled hypertension. Myocardial infarction more than 6 months prior to study entry is permitted.\n* Abnormalities of the cornea based on history (e.g. dry eye syndrome, Sogren's syndrome) including congenital abnormality (e.g. Fuch's dystrophy), abnormal slit-lamp examination using a vital dye (e.g. fluorescein, Bengal-Rose), and/or an abnormal corneal sensitivity test (Schirmer test or similar tear production test).\n* History of interstitial lung disease (ILD).\n* Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry.\n* Previous treatment with yttrium-90 spheres\n* Any condition that is unstable or which could jeopardize the safety of the patient and his/her compliance in the study.\n* Uncontrolled ascites (defined as not easily controlled with diuretic treatment)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival","description":"Overall Survival (OS) was defined as the time from date of randomization to death due to any cause.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"289","spread":null},{"groupId":"OG001","value":"259","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Radiological Tumor Progression (TTP)","description":"TTP was the time from randomization to radiological tumor progression. Participants without radiological tumor progression at the time of analysis were censored at their last date of tumor evaluation. Progressive disease (PD) was defined using Response Evaluation Criteria in Solid Tumors (RECIST version 1.0), as at least a 20% increase in the sum of longest diameter (LD) of measured lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions. Appearance of new lesions also constituted PD.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null},{"groupId":"OG001","value":"122","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease Control","description":"Disease control was defined as the number of participants who had a best response rating of complete response (CR), partial response (PR), or stable disease (SD) according to RECIST assessed by magnetic resonance imaging (MRI) that was confirmed at least 28 days from the first demonstration of that rating. CR: disappearance of all clinical and radiological evidence of target and non-target tumors. PR: at least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum LD. SD: steady state of disease. Neither sufficient shrinkage for PR nor sufficient increase for PD.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"159","spread":null},{"groupId":"OG001","value":"188","spread":null}]}]}]},{"type":"SECONDARY","title":"Health-related Quality of Life and Utility Values as Measured by EQ-5D - Index","description":"The European quality of life scale (5 dimensions) (EQ-5D) questionnaire was given to the participants at each visit. The EQ-5D questionnaire consisted of 5 ordinal categorical responses (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). The scores for the EQ-5D dimensions are assigned according to the level of problems reported (1 'no problems'; 2 'some problems'; 3 'extreme problems'). The 5 health dimensions are summarized into a single score, the EQ-5D index score. The EQ-5D index score has a range of 0 and 1 with 0 representing death and 1 representing perfect health.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.777","spread":null},{"groupId":"OG001","value":"0.774","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.753","spread":null},{"groupId":"OG001","value":"0.749","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.728","spread":null},{"groupId":"OG001","value":"0.724","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.704","spread":null},{"groupId":"OG001","value":"0.700","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.679","spread":null},{"groupId":"OG001","value":"0.675","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.654","spread":null},{"groupId":"OG001","value":"0.651","spread":null}]}]}]},{"type":"SECONDARY","title":"Health-related Quality of Life and Utility Values as Measured by EQ-5D - VAS","description":"Participants indicated on a scale of 0 (worst) to 100 (best) how good or bad their health state was on that particular day.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.397","spread":null},{"groupId":"OG001","value":"74.656","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.649","spread":null},{"groupId":"OG001","value":"72.907","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.900","spread":null},{"groupId":"OG001","value":"71.158","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.151","spread":null},{"groupId":"OG001","value":"69.409","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.402","spread":null},{"groupId":"OG001","value":"67.660","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.653","spread":null},{"groupId":"OG001","value":"65.911","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Duration of Response","description":"Duration of response - RECIST: number of days from the date that CR or PR is first documented to date that PD is first objectively documented or to death before progression. Note: the relevant date is that of the first documentation, not the confirmation date (if participant progressed or died then censored=no) or to last observation if participant did not progress or die then censored=yes note: this last observation date should be the same as that used for time to progression.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"297","spread":null},{"groupId":"OG001","value":"168","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Time to Response","description":"Time to response was the number of days from randomization to the date the CR or PR was documented (with confirmation) (Note: the relevant date is that of the first documentation, not the confirmation date).","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.5","spread":null},{"groupId":"OG001","value":"83.5","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Tumor Response","description":"Tumor response was the proportion of participants with the best tumor response (ie, achieving either a confirmed complete response \\[CR\\] or partial response \\[PR\\], according to Response Evaluation Criteria in Solid Tumors \\[RECIST\\] criteria).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":214,"n":362},"commonTop":["Diarrhea","Diarrhea","Fatigue","Fatigue","Rash/desquamation"]}}}